IDCR, a forum for correctional problem solving,
targets correctional administrators and HIV/AIDS and hepatitis care
providers including physicians, nurses, outreach workers, and case
managers. Continuing Medical Education credits are provided by Medical Education Collaborative to physicians who accurately respond to the questions on the last page of the newsletter.
The
editorial board and contributors to IDCR include national and regional
correctional professionals, selected on the basis of their experience
with HIV and hepatitis care in the correctional setting and their
familiarity with current HIV and hepatitis treatment. We encourage
submissions, feedback, and correspondence from our readership.
ABOUT THIS CONTINUING EDUCATION ACTIVITY
Medical Education Collaborative designates this educational activity
for a maximum of 1 AMA PRA Category 1 Credit(s)T. Physicians should
only claim credit commensurate with the extent of their participation
in the activity. Statements of credit will be mailed within 6 to 8
weeks following the program.
To obtain credit read the Main Article, Table 1, Table 2, Table 3, and 101 sections of the monograph. When completed with all 3 items download the PDF version ( click here to download free adobe reader) | (System requirements) of the monograph located on the sidebar and complete the post test, credit application and evaluation form at the end of the monograph. You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. To receive your certificate mail or fax the post test, credit application and evaluation to:
IDCR
146 Clifford Street
Providence, RI 02903
or fax it to (401)272-7562
The material presented in this activity does not reflect the views of Medical Education Collaborative. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Medical Education Collaborative and IDCR do not recommend the use of any product outside of the labeled indications. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Release Date: 4-30-08
End Date: 4-30-09
|
COMMERCIAL SUPPORTERS
OBJECTIVES
- The learner will be able to describe the recommended treatment, dosing, and monitoring options for the treatment and management of the hepatitis B virus.
- The learner will be able to explain the prevention, screening, and diagnosis measures for the hepatitis B virus.
- The learner will be able to discuss the most significant studies presented at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI).
|
PURPOSE STATEMENT AND TARGET AUDIENCE
The purpose of this monograph is to increase the knowledge of physicians in correctional systems in the prevention, diagnosis, treatment, and management options for hepatitis B and become familar with the information presented at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI).
|
DISCLOSURE OF UNLABELED USE / INVESTIGATIONAL USE
In this activity, the faculty discloses that they will discuss the use of unlabeled and investigational drugs for the treatment of HIV/AIDS.
|
DISCLOSURES
Faculty Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.
In accordance with The Medical Education Collaborative Standards for Commercial Support, the faculty for this
activity have been asked to complete Conflict of Interest Disclosure
forms. |
|
Executive Editor
Anne S. De Groot, MD
Adjunct Associate Professor
Warren Alpert School of Medicine of Brown University
Nothing to Disclose
Editor in Chief
Joseph Bick, MD
Chief Deputy, Clinical Services California Medical Facility
California Department of Corrections
Nothing to Disclose
Deputy Editor
David Alain Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit
The University of North Carolina- Chapel Hill
Disclosures: Speaker: Abbott Laboraties, Gilead Sciences, Inc., Tibotec Therapeutics, Roche Pharmaceuticals, Merck & Co.,
Boehringer-Ingelheim, Bristol-Myers Sqibb.
Renee Ridzon, MD
Senior Program Officer
HIV, TB, Reproductive Health
Bill & Melinda Gates Foundation
Nothing to Disclose
|
|
Disclosures: Maint Article
Jennifer Cocohoba, Pharm. D.
Assistant Clinical Professor
University of California San Francisco School of Pharmacy
Disclosures:
Nothing to disclose
Joseph Bick, MD
Chief Deputy, Clinical Services
California Medical Facility,
California Department of Corrections
Disclosures:
Nothing to disclose
|
Disclosures: Spotlight
Morris Jackson
Treatment Education Coordinator
Center for Health Justice
Disclosures:
Consultant: Gilead Sciences, Serono; Summer Summit Participant: Glaxo SmithKline
|
|
